Funding

STORM Therapeutics

United Kingdom · Biotech

STORM Therapeutics develops cancer medicines that target enzymes responsible for chemical modifications to RNA.

Visit stormtherapeutics.comFunding history

Product

The Cambridge biotechnology company develops STC-15, an investigational oral METTL3 inhibitor. Its clinical programme studies whether changing RNA methylation can reprogram malignant cells in selected cancers.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$56MFast Track Initiative (FTI) — ParticipantIP Group plc — ParticipantM Ventures — ParticipantPfizer Ventures — ParticipantTaiho Ventures — ParticipantUTokyo Innovation Platform Co — Participant

Investors

Fast Track Initiative (FTI)Joined Series CIP Group plcJoined Series CM VenturesJoined Series CPfizer VenturesJoined Series CTaiho VenturesJoined Series CUTokyo Innovation Platform CoJoined Series C

Coverage

Apr 16, 2026STORM Therapeutics · Series C

Similar companies

ALLOXALLOX combines high-throughput genetics, experimental biology and AI to find functional sites on proteins and develop targeted small-molecule medicines.$10.5M · Seed
Dren BioDren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.$350M · Private financing
BioGeometryBioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.Undisclosed · Series A+
Sourcesglobenewswire.com ↗